Coupled plasma filtration adsorption: rationale, technical development and early clinical experience

Area of Science:

• Critical Care Medicine
• Nephrology
• Immunology

Background:

• Sepsis treatment faces challenges, with blood purification offering a theoretical approach to restore humoral homeostasis.
• Excessive inflammation and counterinflammation are key issues in sepsis and multiorgan failure.

Purpose of the Study:

• To evaluate the efficacy and safety of coupled plasma filtration adsorption (CPFA) as an adjuvant therapy for severe sepsis and multiorgan dysfunction.
• To explore the potential of CPFA in modulating inflammatory mediators and improving clinical outcomes.

Main Methods:

• In vitro studies demonstrating CPFA's ability to bind a wide range of inflammatory mediators.
• Animal models investigating the survival benefits of CPFA in endotoxemia.
• Phase I/IIa clinical studies assessing CPFA's impact on hemodynamics and immune function in sepsis patients.

Main Results:

• In vitro and animal studies confirmed the technical efficacy and beneficial effects of CPFA.
• Clinical trials demonstrated that CPFA significantly improves blood pressure in patients with severe sepsis.
• CPFA was shown to restore immune function in patients suffering from sepsis and multiorgan dysfunction.

Conclusions:

• CPFA is a promising extracorporeal therapy for severe sepsis and multiorgan failure.
• The technology offers a nonselective reduction of pro- and anti-inflammatory mediators.
• CPFA improves hemodynamic stability and immune status, warranting further clinical investigation.